Agrimol B inhibits pancreatic ductal adenocarcinoma by induction of lethal mitophagy through decreasing mitochondrial transcription termination factor 3

Abstract

Objective: To investigate the inhibitory effect of the natural polyphenol Agrimol B on pancreatic ductal adenocarcinoma (PDAC) and its underlying molecular mechanisms.

Methods: The effects of Agrimol B on PDAC cell proliferation and apoptosis were assessed using Cell Counting Kit-8, colony formation, and flow cytometry assays. An in vivo PDAC xenograft mouse model was established for evaluation. Label-free quantitative proteomics, western blotting, immunofluorescence, and transmission electron microscopy were employed to analyze mitochondrial function, autophagy, and related signaling pathways. A patient-derived organoid model was used to evaluate the synergistic effects of Agrimol B with first-line chemotherapy drugs.

Results: Agrimol B significantly inhibited PDAC growth and induced apoptosis both in vitro and in vivo. Mechanistically, Agrimol B downregulated the expression of mitochondrial transcription termination factor 3, and promoted the accumulation of PTEN induced kinase 1 (PINK1) in mitochondria and Parkin translocation, thereby excessively activating PINK1/Parkin-dependent mitophagy. Concurrently, Agrimol B blocked lysosome biogenesis, leading to autophagosome accumulation and impaired autophagic flux. This dysfunctional autophagy ultimately mediated the anti-PDAC effect of Agrimol B. Furthermore, in PDAC patient-derived organoids, Agrimol B exhibited synergistic effects with first-line chemotherapy drugs such as gemcitabine and nab-paclitaxel.

Conclusion: Agrimol B exerts its anti-PDAC effects by downregulating mitochondrial transcription termination factor 3, hyperactivating PINK1/Parkin-mediated mitophagy, and obstructing autophagic flux. Its synergistic effect with chemotherapy drugs provides experimental evidence supporting its potential clinical translation.

Keywords

pancreatic ductal adenocarcinoma / Agrimol B / mitophagy / MTERF3 / PINK1/Parkin

References

[1] Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol 2021; 18:493-502. https://doi.org/10.1038/s41575-021-00457-x.

[2] Zhou K, Liu Y, Tang C et al. Pancreatic cancer: pathogenesis and clinical studies. MedComm 2025; 6:e70162. https://doi.org/10.1002/mco2.70162.

[3] Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 2023; 164:752-65. https://doi.org/10.1053/j.gastro.2023.02.012.

[4] Farhangnia P, Khorramdelazad H, Nickho H et al. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol 2024; 17:40. https://doi.org/10.1186/s13045-024-01561-6.

[5] Bear AS, Vonderheide RH, O’Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell 2020; 38:788-802. https://doi.org/10.1016/j.ccell.2020.08.004.

[6] Lu Y, Li Z, Zhang S et al. Cellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation. Theranostics 2023; 13:736-66. https://doi.org/10.7150/thno.79876.

[7] Picca A, Faitg J, Auwerx J et al. Mitophagy in human health, ageing and disease. Nat Metab 2023; 5:2047-61. https://doi.org/10.1038/s42255-023-00930-8.

[8] Ma Y, Zheng Y, Zhou Y et al. Mitophagy involved the biological processes of hormones. Biomed Pharmacother 2023; 167:115468. https://doi.org/10.1016/j.biopha.2023.115468.

[9] Wang S, Long H, Hou L et al. The mitophagy pathway and its implications in human diseases. Sig Transduct Target Ther 2023; 8:304. https://doi.org/10.1038/s41392-023-01503-7.

[10] Zheng Y, Ma Y, Xiong Q et al. The role of artificial intelligence in the development of anticancer therapeutics from natural polyphenols: Current advances and future prospects. Pharmacol Res 2024; 208:107381. https://doi.org/10.1016/j.phrs.2024.107381.

[11] Ma Y, Mu J, Gou X et al. Precision medication based on the evaluation of drug metabolizing enzyme and transporter functions. Precis Clin Med 2025; 8:pbaf004. https://doi.org/10.1093/pcmedi/pbaf004.

[12] Liu YT, Zhang LL, Jiang ZY et al. Applications of Artificial Intelligence in Biotech Drug Discovery and Product Development. MedComm 2020; 6:e70317. https://doi.org/10.1002/mco2.70317.

[13] Zhang R, Yu J, Guo Z et al. Camptothecin-based prodrug nanomedicines for cancer therapy. Nanoscale 2023; 15:17658-97. https://doi.org/10.1039/D3NR04147F.

[14] Wang X, Zhuang Y, Wang Y et al. The recent developments of camptothecin and its derivatives as potential anti-tumor agents. Eur J Med Chem 2023; 260:115710. https://doi.org/10.1016/j.ejmech.2023.115710.

[15] Smith ER, Wang JQ, Yang DH et al. Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resist Updat 2022; 65:100881. https://doi.org/10.1016/j.drup.2022.100881.

[16] Yadav G, Ahmaruzzaman M. New generation advanced nanomaterials for photocatalytic abatement of phenolic compounds. Chemosphere 2022; 304:135297. https://doi.org/10.1016/j.chemosphere.2022.135297.

[17] Yi Y, Tang HS, Sun Y et al. Comprehensive characterization of lotus root polysaccharide-phenol complexes. Food Chem 2022; 366:130693. https://doi.org/10.1016/j.foodchem.2021.130693.

[18] Ming T, Tao Q, Tang S et al. Curcumin: An epigenetic regulator and its application in cancer. Biomed Pharmacother 2022; 156:113956. https://doi.org/10.1016/j.biopha.2022.113956.

[19] Aggarwal V, Tuli HS, Tania M et al. Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement. Semin Cancer Biol 2022; 80:256-75. https://doi.org/10.1016/j.semcancer.2020.05.011.

[20] He N, Shen G, Jin X et al. Resveratrol suppresses microglial activation and promotes functional recovery of traumatic spinal cord via improving intestinal microbiota. Pharmacol Res 2022; 183:106377. https://doi.org/10.1016/j.phrs.2022.106377.

[21] Shu L, Hou X, Song G et al. Comparative analysis of long non-coding RNA expression profiles induced by resveratrol and metformin treatment for hepatic insulin resistance. Int J Mol Med 2021; 48:206. https://doi.org/10.3892/ijmm.2021.5039.

[22] Xiang D, Yang W, Fang Z et al. Agrimol B inhibits colon carcinoma progression by blocking mitochondrial function through the PGC-1alpha/NRF1/TFAM signaling pathway. Front. Oncol. 2022; 12:1055126. https://doi.org/10.3389/fonc.2022.1055126.

[23] Hnit SST, Ding R, Bi L et al. Agrimol B present in Agrimonia pilosa Ledeb impedes cell cycle progression of cancer cells through G(0) state arrest. Biomed Pharmacother 2021; 141:111795. https://doi.org/10.1016/j.biopha.2021.111795.

[24] Dong L, Luo L, Wang Z et al. Targeted degradation of NDUFS1 by agrimol B promotes mitochondrial ROS accumulation and cytotoxic autophagy arrest in hepatocellular carcinoma. Free Radical Biol Med 2024; 220:111-24. https://doi.org/10.1016/j.freeradbiomed.2024.04.242.

[25] Liang Z, Yang P, Zhu X et al. The irreplaceable role of pathology for the clinical translation of patient-derived organoids in precision medicine. Precis Clin Med 2025; 8:pbaf032. https://doi.org/10.1093/pcmedi/pbaf032.

[26] Fang Z, Ran H, Zhang Y et al. AlphaFold 3: an unprecedent opportunity for fundamental research and drug development. Precis Clin Med 2025; 8:pbaf015. https://doi.org/10.1093/pcmedi/pbaf015.

[27] Tang R, Xu J, Wang W et al. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Cell Reports Medicine 2023; 4:101234. https://doi.org/10.1016/j.xcrm.2023.101234.

[28] Cui Zhou D, Jayasinghe RG, Chen S et al. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Nat Genet 2022; 54:1390-405. https://doi.org/10.1038/s41588-022-01157-1.

[29] Huang S, Lin L, Ma Y et al. Scoparone induces autophagic cell death via the PAK1/AKT axis in colorectal cancer. Eur J Pharmacol 2023; 959:176091. https://doi.org/10.1016/j.ejphar.2023.176091.

[30] Weng N, Qin S, Liu J et al. Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. Acta Pharmaceutica Sinica B 2022; 12:3085-102. https://doi.org/10.1016/j.apsb.2022.01.018.

[31] Li Q, Qin S, Tian H et al. Nano-econazole enhanced PD-L1 checkpoint blockade for synergistic antitumor immunotherapy against pancreatic ductal adenocarcinoma. Small 2023; 19:e2207201. https://doi.org/10.1002/smll.202207201.

[32] Liu R, Li Q, Qin S et al. Sertaconazole-repurposed nanoplatform enhances lung cancer therapy via CD44-targeted drug delivery. J Exp Clin Cancer Res 2023; 42:188. https://doi.org/10.1186/s13046-023-02766-2.

[33] Park CB, Asin-Cayuela J, Camara Y et al. MTERF3 is a negative regulator of mammalian mtDNA transcription. Cell 2007; 130:273-85. https://doi.org/10.1016/j.cell.2007.05.046.

[34] Zheng Z, Zhao Y, Yu H et al. Suppressing MTERF3 inhibits proliferation of human hepatocellular carcinoma via ROSmediated p38 MAPK activation. Commun Biol 2024; 7:18. https://doi.org/10.1038/s42003-023-05664-7.

[35] Wang J, Liu K, Li J et al. Constructing and evaluating a mitophagy-related gene prognostic model: implications for immune landscape and tumor biology in lung adenocarcinoma. Biomolecules, 2024; 14:228. https://doi.org/10.3390/biom14020228.

[36] Tu DY, Cao J, Zhou J et al. Identification of the mitophagyrelated diagnostic biomarkers in hepatocellular carcinoma based on machine learning algorithm and construction of prognostic model. Front Oncol 2023; 13:1132559. https://doi.org/10.3389/fonc.2023.1132559.

[37] Patra S, Pradhan B, Nayak R et al. Dietary polyphenols in chemoprevention and synergistic effect in cancer: Clinical evidences and molecular mechanisms of action. Phytomedicine 2021; 90:153554. https://doi.org/10.1016/j.phymed.2021.153554.

[38] Tang J, Li L, Chen Z et al. Agrimol B alleviates cisplatininduced acute kidney injury by activating the Sirt1/Nrf2 signaling pathway in mice. Acta Biochim Biophys Sin (Shanghai) 2024; 56:551-63.